Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

By J. Colombel, N. Ferrari, H. Debuysère, P. Marteau, J. Gendre, Bruno Bonaz, J. Soulé, R. Modigliani, Y. Touze, P. Catala and 2 more. Gastroenterology, 2000

619 citations recorded by the source corpus.

Subfields: Public Health, Environmental and Occupational Health, Rheumatology

View Paper: https://www.semanticscholar.org/paper/491b32f4d05601ba847cd6c02e31f760604a7a8c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Pharmacogenomics and individualized drug therapy. (2006, background): “Neglecting the impact of nongenetic factors on a drug-response phenotype has led to claims that the presence of deficient alleles of thiopurine S-methyltransferase (TPMT) is a poor predictor of severe myelosuppression caused by the use of 6-mercaptopurine or azathioprine (13).”
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (2010, background): “However, only about a quarter of cases of leukopenia in practice are associated with one of these genetic polymorphisms (”
Guidelines for the management of inflammatory bowel disease in adults (2011, neutral): “Manufacturers recommend weekly full blood counts (FBCs) for the first 8 weeks of therapy followed by blood tests at least every 3 months. There is no evidence that this is effective. One fairly common practice is to perform a full blood count every 2–4 weeks for 2 months and then every 4–8 weeks. Th”